Soligenix Aims To Push The Boundaries In Treating Rare Diseases

By Johnny Rice Benzinga

DETROIT, MICHIGAN - February 25, 2025 (NEWMEDIAWIRE) - Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. (NASDAQ: SNGX), was recently a guest on Benzingas All-Access.

Soligenix, a late-stage biopharmaceutical company, is focused on developing and commercializing treatments for rare diseases. The company's key focus is on HyBryte(TM), a novel photodynamic therapy for cutaneous T-cell lymphoma, and the expansion of synthetic hypericin into psoriasis and other inflammatory diseases.

Schaber shared exciting updates from the companys phase 3 study of HyBryte. Preliminary results are expected in mid 2026.

Watch the full interview here: https://youtu.be/qs6MxADPsAA

Featured photo by Online Marketing on Unsplash .

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Copyright 2025 JCN Newswire . All rights reserved.

You May Also Be Interested In

• Sampo plc’s share buybacks week 28/2026
• SCENESSE® approved for EPP in Canada
• Climate and Net Zero Energy Debate Challenge issued by Friends of Science Society to UN Group by Same Name